Science Exchange announces a collaboration with AUM BioTech, a Philadelphia-based startup, to advance genetic research and significantly cut short drug discovery and development time. Science Exchange will now offer AUM BioTech’s self-delivering, next-generation RNA silencing products and alternatives to conventional CRISPR, siRNA and shRNA approaches.
As a part of this alliance, Science Exchange users will gain access to AUM BioTech’s 300,000-plus customized and cutting-edge RNA silencing products targeting thousands of genetic targets powered by proprietary FANA technology, a technology platform composed of antisense oligonucleotide (AON) chemistries. These products can be used to target messenger RNA (mRNA), microRNA (miRNA) and long non-coding (lncRNA) for a broad spectrum of genetic studies. They can also be used to target viral, fungal and bacterial RNA. AUM BioTech’s FANA antisense oligonucleotides (FANA ASOs) can be self-delivered both in in vitro and in vivo models without the use of any conjugates, carriers or formulations and can be used for basic and translational research.
“With FANA, our goal is to shorten the drug discovery and development time and help bring clinical compounds to market much faster,” said Veenu Aishwarya, founder and CEO of AUM BioTech. “This strategic alliance with Science Exchange will grant its users on-demand access to our FANA technology and help them reduce the time and effort needed to understand the function of genes and their link to diseases.”
“AUM BioTech is an innovative company that has developed revolutionary genetic research products to significantly advance biomedical R&D and fast-track drug discovery, leading to more effective therapeutic development,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. "We are thrilled to collaborate with AUM BioTech and further advance our shared goal to help the global scientific community find cures for diseases.”